Swiss fine chemicals producer Lonza has closed the acquisition of US-based InterHealth Nutraceuticals from Kainos Capital for a price of up to $300 million, split into an upfront payment and an earn-out payment. Lonza said the integration of the nutraceuticals producer headquartered in California, which develops, manufactures and markets proprietary value-added nutritional ingredients for use in dietary supplements, will be immediately earnings accretive, as the company’s portfolio aligns closely with its own.

The California company will become part of Lonza’s consumer care business unit, but will retain its own facilities and employees. The combination of the two businesses will allow the Swiss company to offer InterHealth’s more than 15 branded ingredients, including the new acquisition’s cornerstone ingredient, UC-II, which is said to be revolutionizing the joint-health segment.

With the acquisition, CEO Richard Ridinger said Lonza “will be able to harness Interhealth’s proven management and branding capabilities and leverage them to a global level.” He said the acquisition is a step toward the company’s goal of becoming the world’s leading and most-trusted supplier to the pharmaceutical, biotech and specialty ingredients markets.